Drug reference

sulfamethopyrazine

Sulfonamide, ultralong acting · Antimalarial (in combination), Antibacterial, Antiprotozoal

Sulfonamide, ultralong actingAntimalarial (in combination), Antibacterial, Antiprotozoal

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Not yet extracted

Indications

malaria (especially chloroquine resistant P. falciparum, in combination with pyrimethamine)pneumocystis jiroveci pneumonia (in AIDS patients, in combination with pyrimethamine)toxoplasmosis (in combination with pyrimethamine)

Pharmacokinetics

Half-life

5-9 days

Protein binding

high plasma protein binding

Excretion

slow renal excretion

Side effects

Serious

serious cutaneous reactions

Related guidelines

Malaria treatment

ICMR · Infectious Disease · 2021

Community-acquired pneumonia

IDSA · Pulmonology · 2019

Drug-resistant tuberculosis

RNTCP · Pulmonology · 2025

Community-acquired pneumonia

ICMR · Pulmonology · 2022

Childhood pneumonia and respiratory infection

MOHFW · Paediatrics · 2021

Ask House about sulfamethopyrazine

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team